FDA expands Merck drug's approval to treat lung cancer
WASHINGTON (AP) — Federal health officials on Friday expanded approval of an innovative Merck drug to treat patients with an advanced form of the most common lung cancer.
The Food and Drug Administration approved Keytruda for advanced non-small cell lung cancer patients who have seen their tumors spread after taking other therapies.
A day earlier, the FDA announced accelerated approval for a combination of two immunotherapies from Bristol-Myers to treat patients with a genetic variation of advanced melanoma.